A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Completed · Phase 2 · Has a placebo group

Conditions studied: Influenza

In brief

The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.

Key facts

Study ID

NCT00958243

Run by

Seqirus

People needed

473

Starts

2009-08-01

Expected to finish

2010-04-01

Last updated by the study team

2018-05-23

Who can join

Age: 1 and older, up to 9. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female aged >= 6 months to < 9 years at the time of the first study vaccination.
• For children < 3 years of age at the time of first vaccination, born at or after 36 weeks gestation.

You may not qualify if…

• Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine

Where it is running

• Study site — Chandler, Arizona, United States
• Study site — Melbourne, Florida, United States
• Study site — Bardstown, Kentucky, United States
• Study site — Metairie, Louisiana, United States
• Study site — Omaha, Nebraska, United States
• Study site — Austintown, Ohio, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Latrobe, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Austin, Texas, United States
• Study site — Fort Worth, Texas, United States
• Study site — Houston, Texas, United States
• Study site — Murray, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.